FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
As of June 2013, the Dutch Molecular Pathology Center (DMPC) and InnoSer will combine their expertise and services. InnoSer will take advantage of the DMPC’s specific expertise in pathology for the analysis of genetically modified animals on behalf of its customers. The combined efforts will enable them to optimally facilitate their clients in finding and analysing models and therapies for human diseases. read more
Trinean, the leading provider of microfluidic spectrophotometry platforms, today announced it has entered into a long-term agreement with Bayer CropScience to supply DropSense96 and Xpose droplet readers along with its proprietary cDrop spectral analysis software to Bayer CropScience's global operations. Bayer CropScience will be using Trineans technology for High Throughput quantification and quality control of isolated biomolecules to assure robust outcome of genetic tests in its molecular breeding program. read more
OpGen, Inc., today announced the company has entered into a strategic collaboration with Applied Maths NV, the market leader in bioinformatics and analytical solutions for public health and research laboratories, to provide advanced software tools for microbial genomics and molecular strain typing. Under the agreement, Applied Maths has incorporated a Whole Genome Mapping module into the company’s new BioNumerics 7 software suite, providing customers with seamless access to a new set of analytical tools for molecular typing and comparative genomics of microbial pathogens. read more
BITS, the bio-informatics training and service facility of the Belgian life sciences research institute VIB, has chosen qbase+ as the software to accelerate its qPCR analyses. The qbase+ group license is available for more than ten VIB departments covering over 1000 researchers. read more
Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3. Upon successful completion of the study, expected in Q2 2015, AbbVie will pay Galapagos $50 million. The terms of the collaboration extension are in addition to previously agreed upon financial terms. AbbVie will be responsible for funding and performing clinical development beyond Phase 2, and completing regulatory and commercialization activities. read more
